Markets:

Overview

News

Currencies

International

Treasuries

Denali Therapeutics Inc. - Common Stock (NQ:DNLI)

18.77 -0.41 (-2.14%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Denali Therapeutics Inc. - Common Stock

< Previous 1 2 3 Next >

Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst ↗

September 06, 2023

B Riley Securities initiated coverage on Denali Therapeutics Inc (NASDAQ: DNLI) with a Buy rating and a

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023 ↗

September 06, 2023

Via Benzinga

Analyst Expectations for Denali Therapeutics's Future ↗

August 31, 2023

Via Benzinga

Where Denali Therapeutics Stands With Analysts ↗

August 10, 2023

Via Benzinga

Analyst Expectations for Denali Therapeutics's Future ↗

June 21, 2023

Within the last quarter, Denali Therapeutics (NASDAQ:DNLI) has observed the following analyst ratings:

Via Benzinga

Why Shares of Denali Therapeutics Are Up Monday ↗

May 15, 2023

Analysts maintained their buy ratings on the clinical-stage biotech company.

Via The Motley Fool

Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now ↗

June 29, 2023

With longevity back in the news, many investors are wondering which biotech stocks to buy to best cash in on the growing trend.

Via InvestorPlace

Denali Says Hunter Syndrome Candidate Lowers Disease-Associated Biomarker ↗

June 20, 2023

Denali Therapeutics Inc (NASDAQ: DNLI) announced new interim results from the ongoing open-label, single-arm Phase 1/2 study of DNL310 IDS in children with

Via Benzinga

Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure ↗

June 05, 2023

Via Benzinga

Biogen Moves Deeper In Alzheimer's With Denali ↗

April 14, 2023

Biogen exercised their rights to a Denali Alzheimer's drug. What does this mean longer term to the field and the companies?

Via Talk Markets

Where Denali Therapeutics Stands With Analysts ↗

April 12, 2023

Via Benzinga

Where Denali Therapeutics Stands With Analysts ↗

March 02, 2023

Via Benzinga

Denali Therapeutics Reveals New Interim Data From Early-Stage Hunter Syndrome Study ↗

February 23, 2023

Via Benzinga

Expert Ratings for Denali Therapeutics ↗

January 30, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023 ↗

January 30, 2023

Via Benzinga

Why Denali Therapeutics' Stock Rose 6.6% on Wednesday ↗

November 02, 2022

The biopharmaceutical stock was actually up as much as 12.4% before falling a bit at the close.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022 ↗

November 02, 2022

Upgrades

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022 ↗

December 05, 2022

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

October 18, 2022

Gainers

Via Benzinga

Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday ↗

September 29, 2022

Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial...

Via Benzinga

Netflix, Biogen And Other Big Gainers From Wednesday ↗

September 29, 2022

U.S. stocks closed higher with the Dow Jones surging more than 500 points on Wednesday. Here is the list of some big stocks recording gains in the previous session.

Via Benzinga

Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session ↗

September 28, 2022

Gainers

Via Benzinga

4 Undervalued Biotech Stocks to Add to Your Buy List ↗

April 20, 2022

These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022 ↗

June 23, 2022

Upgrades

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

April 20, 2022

On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new...

Via Benzinga

AbbVie Stock Breaks Its Stride As Key Executive Departs For Flagship ↗

April 13, 2022

Flagship Pioneering is swiping one of AbbVie's biggest names.

Via Investor's Business Daily

7 F-Rated Stocks to Avoid During the Downturn ↗

March 23, 2022

It's easy to find hard hit stocks in this market, but what's harder to determine is which stocks are truly F-rated stocks among the losers.

Via InvestorPlace

Denali Receives Formal Letter Regarding FDA Hold On Alzheimer's Potential Program ↗

February 14, 2022

As previously announced, Denali Therapeutics Inc (NASDAQ: DNLI) was informed via e-mail communication from the FDA that DNL919 (ATV:TREM2) Investigational New Drug (IND...

Via Benzinga

The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly ↗

February 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More ↗

February 06, 2022

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Denali Therapeutics Inc. - Common Stock (NQ:DNLI)

Headline News about Denali Therapeutics Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today